8,405 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. purchased a new position in Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,405 shares of the medical research company’s stock, valued at approximately $472,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of EXAS. Geode Capital Management LLC grew its stake in shares of Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after purchasing an additional 7,873 shares during the period. Champlain Investment Partners LLC grew its stake in shares of Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after purchasing an additional 245,980 shares during the period. Bellevue Group AG grew its stake in shares of Exact Sciences by 25.1% during the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after purchasing an additional 290,585 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Exact Sciences by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company’s stock worth $74,785,000 after purchasing an additional 38,849 shares during the period. Finally, Groupama Asset Managment acquired a new stake in shares of Exact Sciences during the 3rd quarter worth approximately $821,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Up 0.9 %

Shares of EXAS opened at $47.06 on Friday. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The firm’s fifty day moving average is $52.88 and its two-hundred day moving average is $59.35. The stock has a market cap of $8.74 billion, a PE ratio of -8.45 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. Research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EXAS. TD Cowen raised their price objective on shares of Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. BTIG Research lifted their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Scotiabank boosted their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Barclays cut their price target on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, Exact Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $71.94.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.